Ami Desai, MD
Internal Medicine · Chicago, ILNPI 1710097795
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.7%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Y-mabs Therapeutics, Inc. at 28.2% of the total. Reporting peaked in 2022 at $3,085 and has fallen 93.2% since, to $208 in 2025. Among internal medicine clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 168 payments — averaging $61.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Y-mabs Therapeutics, Inc.$3K
- GSK$2K
- F. Hoffmann-la Roche AG$1K
- Recordati_rare_diseases_inc.$680
- Novartis$580
- Novo Nordisk$404
- plus $2K from 26 others
Across 38 payments — averaging $1229.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$39K
- F. Hoffmann-la Roche AG$8K
What the payments were for
- Consulting fees$5,75556%
- Speaking & faculty fees$1,31413%
- Travel & lodging$2112%
- Food & beverage$3,05330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Y-mabs Therapeutics, Inc. | 2 | $2,911 |
| GSK | 4 | $2,433 |
| F. Hoffmann-la Roche AG | 5 | $1,314 |
| Recordati_rare_diseases_inc. | 1 | $680 |
| Novartis | 27 | $580 |
| Novo Nordisk | 21 | $404 |
| Amgen | 11 | $266 |
| Merck | 12 | $229 |
| Pfizer | 12 | $196 |
| Exact Sciences | 6 | $153 |
| CSL Behring | 5 | $126 |
| Johnson & Johnson(2 entities) | 5 | $124 |
| AstraZeneca | 8 | $103 |
| Boehringer Ingelheim | 5 | $98 |
| Lilly USA, LLC | 5 | $97 |
| E.r. Squibb & Sons, L.L.C. | 7 | $94 |
| Teva Pharmaceuticals USA, Inc. | 6 | $78 |
| AbbVie(2 entities) | 4 | $76 |
| Gilead | 4 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $59 |
| Alk-abello, Inc | 3 | $39 |
| Seqirus USA Inc | 2 | $32 |
| Abbott | 1 | $28 |
| Ironwood Pharmaceuticals, Inc | 1 | $24 |
| Astellas Pharma US Inc | 1 | $21 |
| Medtronic | 1 | $18 |
| Radius Health, Inc. | 1 | $17 |
| Vivus LLC | 1 | $16 |
| Pharming Healthcare, Inc. | 1 | $16 |
| United Therapeutics Corporation | 1 | $15 |
| Avion Pharmaceuticals | 1 | $12 |
| Dynavax Technologies Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DANYELZA$2,911
- Non-Covered Product$1,314
- Sylvant$680
How this compares
$10,333 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 50 | $55,467 |
| JardianceEmpagliflozin | 31 | $49,808 |
| OzempicSemaglutide | 33 | $42,353 |
| XareltoRivaroxaban | 17 | $25,338 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $13,415 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 34 | $3,932 |
| SynthroidLevothyroxine Sodium | 44 | $3,486 |
| Rosuvastatin Calcium | 213 | $3,165 |
| Atorvastatin Calcium | 301 | $3,137 |
| Estradiol | 31 | $3,029 |
| Levothyroxine Sodium | 137 | $2,189 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $2,052 |
| Losartan Potassium | 141 | $1,770 |
| Escitalopram Oxalate | 68 | $1,643 |
| PaxlovidNirmatrelvir/Ritonavir | 14 | $1,462 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $196 | $56,92964 claims |
| Boehringer IngelheimJardiance | $98 | $49,80831 claims |
| Novo NordiskOzempic | $404 | $42,35333 claims |
| Johnson & JohnsonXarelto | $124 | $25,33817 claims |
| GSKBreo Ellipta | $2,433 | $13,41525 claims |
| AbbVieSynthroid | $76 | $3,48644 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Chicago
- Merle DiamondChicago$1.1M
- Robert KushnerChicago$516K
- Romeo UrsuaChicago$420K
- Peter O DonnellChicago$318K
- George UrbanChicago$258K
- Kristen PallokChicago$256K
- George NissanChicago$252K
- Luke LaffinChicago$162K
- Daniel CatenacciChicago$161K
- Hiren ShahChicago$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.